{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:05Z","timestamp":1786979885583,"version":"build-2736575974"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T00:00:00Z","timestamp":1463097600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s00259-016-3395-4","type":"journal-article","created":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T07:00:34Z","timestamp":1463122834000},"page":"2072-2083","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Current knowledge on the sensitivity of the 68Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours"],"prefix":"10.1007","volume":"43","author":[{"given":"Irene","family":"Virgolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kroiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"von Guggenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert","family":"Prommegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Warwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Nilica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"llanos Geraldo","family":"Roig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Uprimny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,13]]},"reference":[{"key":"3395_CR1","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1245\/s10434-015-4826-3","volume":"23","author":"TC Chua","year":"2016","unstructured":"Chua TC, Yang TX, Gill AJ, Samra JS. Systematic review and meta-analysis of enucleation versus standardized resection for small pancreatic lesions. Ann Surg Oncol. 2016;23:592\u20139.","journal-title":"Ann Surg Oncol"},{"key":"3395_CR2","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000335587","volume":"95","author":"M Falconi","year":"2012","unstructured":"Falconi M, Bartsch DK, Eriksson B, et al. ENETS Consensus guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumours. Neuroendocrinology. 2012;95:120\u201334.","journal-title":"Neuroendocrinology"},{"key":"3395_CR3","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1177\/107327480801500406","volume":"15","author":"PJ Hodul","year":"2008","unstructured":"Hodul PJ, Strosberg JR, Kvols LK. Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated? Cancer Control. 2008;15:314\u201321.","journal-title":"Cancer Control"},{"key":"3395_CR4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/RLU.0b013e3181d6677c","volume":"35","author":"A Versari","year":"2010","unstructured":"Versari A, Camellini L, Carlinfante G, et al. Ga-68 DOTATOC-PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study. Clin Nucl Med. 2010;35:321\u20138.","journal-title":"Clin Nucl Med"},{"key":"3395_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000367850","volume":"101","author":"L Bodei","year":"2015","unstructured":"Bodei L, Sundin A, Kidd M, Prasad V, Modlin IM. The status of neuroendocrine tumor imaging: from darkness to light? Neuroendocrinology. 2015;101:1\u201317.","journal-title":"Neuroendocrinology"},{"issue":"26","key":"3395_CR6","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2007.15.1126","volume":"20","author":"KP Koopmans","year":"2008","unstructured":"Koopmans KP, Neels OC, Kema IP, et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol. 2008;20(26):1489\u201395.","journal-title":"J Clin Oncol"},{"key":"3395_CR7","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2967\/jnumed.115.157768","volume":"56","author":"K Antwi","year":"2015","unstructured":"Antwi K, Fani M, Nicolas G, Rottenburger C, Heye T, Reubi JC, et al. Localization of hidden insulinomas with 68Ga-DOTA-exendin-4 PET\/CT: a pilot study. J Nucl Med. 2015;56:1075\u20138.","journal-title":"J Nucl Med"},{"key":"3395_CR8","first-page":"551","volume":"47","author":"JC Reubi","year":"1987","unstructured":"Reubi JC, Maurer R, von Werder K, Torhorst J, Klijn JG, Lamberts SW. Somatostatin receptors in human endocrine tumors. Cancer Res. 1987;47:551\u20138.","journal-title":"Cancer Res"},{"key":"3395_CR9","first-page":"690","volume":"54","author":"I Virgolini","year":"1994","unstructured":"Virgolini I, Yang Q, Li S, et al. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Cancer Res. 1994;54:690\u2013700.","journal-title":"Cancer Res"},{"key":"3395_CR10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/BF01236270","volume":"17","author":"F Malaisse-Lagae","year":"1979","unstructured":"Malaisse-Lagae F, Stefan Y, Cox J, Perrelet A, Orci L. Identification of a lobe in the adult human pancreas rich in pancreatic polypeptide. Diabetologia. 1979;17:361\u20135.","journal-title":"Diabetologia"},{"key":"3395_CR11","first-page":"126","volume":"8","author":"GM Portela-Gomes","year":"2000","unstructured":"Portela-Gomes GM, Stridsberg M, Grimelius L, Oberg K, Janson ET. Expression of the five different somatostatin receptor subtypes in endocrine cells of the pancreas. Appl Immunohistochem Mol Morphol. 2000;8:126\u201332.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"3395_CR12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/291076a0","volume":"291","author":"L Mandarino","year":"1981","unstructured":"Mandarino L, Stenner D, Blanchard W, Nissen S, Gerich J, Ling N, et al. Selective effects of somatostatin-14, -25 and -28 on in vitro insulin and glucagon secretion. Nature. 1981;291:76\u20137.","journal-title":"Nature"},{"key":"3395_CR13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/frne.1999.0183","volume":"20","author":"YC Patel","year":"1999","unstructured":"Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157\u201398.","journal-title":"Front Neuroendocrinol"},{"key":"3395_CR14","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s002590100639","volume":"28","author":"M Hofmann","year":"2001","unstructured":"Hofmann M, Maecke H, B\u00f6rner R, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data. Eur J Nucl Med. 2001;28:1751\u20137.","journal-title":"Eur J Nucl Med"},{"key":"3395_CR15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s002590050034","volume":"27","author":"JC Reubi","year":"2000","unstructured":"Reubi JC, Sch\u00e4r JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273\u201382.","journal-title":"Eur J Nucl Med"},{"key":"3395_CR16","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1007\/s00259-006-0317-x","volume":"34","author":"P Antunes","year":"2007","unstructured":"Antunes P, Ginj M, Zhang H, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging. 2007;34:982\u201393.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3395_CR17","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1007\/s00259-003-1255-5","volume":"30","author":"D Wild","year":"2003","unstructured":"Wild D, Schmitt JS, Ginj M, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging. 2003;30:1338\u201347.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3395_CR18","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1677\/ERC-09-0078","volume":"17","author":"DJ Kwekkeboom","year":"2010","unstructured":"Kwekkeboom DJ, Kam BL, van Essen M, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010;17:R53\u201373.","journal-title":"Endocr Relat Cancer"},{"key":"3395_CR19","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1007\/s00259-010-1512-3","volume":"37","author":"I Virgolini","year":"2010","unstructured":"Virgolini I, Ambrosini V, Bomanji JB, et al. Procedure guidelines for PET\/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37:2004\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3395_CR20","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2967\/jnumed.106.035667","volume":"48","author":"M Gabriel","year":"2007","unstructured":"Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508\u201318.","journal-title":"J Nucl Med"},{"key":"3395_CR21","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.2967\/jnumed.108.053421","volume":"50","author":"M Gabriel","year":"2009","unstructured":"Gabriel M, Oberauer A, Dobrozemsky G, et al. 68Ga-DOTA-Tyr3\u2212octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med. 2009;50:1427\u201334.","journal-title":"J Nucl Med"},{"key":"3395_CR22","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s00259-012-2309-3","volume":"40","author":"A Kroiss","year":"2013","unstructured":"Kroiss A, Putzer D, Decristoforo C, et al. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET\/CT. Eur J Nucl Med Mol Imaging. 2013;40:514\u201323.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3395_CR23","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1007\/s00259-011-1875-0","volume":"38","author":"A Al-Ibraheem","year":"2011","unstructured":"Al-Ibraheem A, Bundschuh RA, Notni J, et al. Focal uptake of 68Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours? Eur J Nucl Med Mol Imaging. 2011;38:2005\u201313.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3395_CR24","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1007\/s00330-011-2199-y","volume":"21","author":"R Kumar","year":"2011","unstructured":"Kumar R, Sharma P, Garg P, et al. Role of 68Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours. Eur Radiol. 2011;21:2408\u201316.","journal-title":"Eur Radiol"},{"key":"3395_CR25","first-page":"61","volume":"54","author":"V Prasad","year":"2010","unstructured":"Prasad V, Baum RP. Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. Q J Nucl Med Mol Imaging. 2010;54:61\u20137.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"3395_CR26","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/RLU.0b013e3182485110","volume":"37","author":"H Jacobsson","year":"2012","unstructured":"Jacobsson H, Larsson P, Jonsson C, Jussing E, Gryb\u00e4ck P. Normal uptake of 68Ga-DOTA-TOC by the pancreas uncinate process mimicking malignancy at somatostatin receptor PET. Clin Nucl Med. 2012;37:362\u20135.","journal-title":"Clin Nucl Med"},{"key":"3395_CR27","doi-asserted-by":"crossref","first-page":"886","DOI":"10.2967\/jnumed.111.088328","volume":"52","author":"P Castellucci","year":"2011","unstructured":"Castellucci P, Pou Ucha J, Fuccio C, et al. Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET\/CT. J Nucl Med. 2011;52:886\u201390.","journal-title":"J Nucl Med"},{"key":"3395_CR28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00259-009-1205-y","volume":"37","author":"V Prasad","year":"2010","unstructured":"Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP. Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET\/CT. Eur J Nucl Med Mol Imaging. 2010;37:67\u201377.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3395_CR29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/RLU.0b013e3182393404","volume":"37","author":"Y Krausz","year":"2012","unstructured":"Krausz Y, Rubinstein R, Appelbaum L, et al. Ga-68 DOTA-NOC uptake in the pancreas: pathological and physiological patterns. Clin Nucl Med. 2012;37:57\u201362.","journal-title":"Clin Nucl Med"},{"key":"3395_CR30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00261-014-0219-5","volume":"40","author":"P Sharma","year":"2015","unstructured":"Sharma P, Arora S, Dhull VS, et al. Evaluation of 68Ga-DOTANOC PET\/CT imaging in a large exclusive population of pancreatic neuroendocrine tumors. Abdom Imaging. 2015;40:299\u2013309.","journal-title":"Abdom Imaging"},{"key":"3395_CR31","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.2967\/jnumed.111.091165","volume":"52","author":"TD Poeppel","year":"2011","unstructured":"Poeppel TD, Binse I, Petersenn S, et al. 68Ga-DOTATOC versus 68Ga-DOTATATE PET\/CT in functional imaging of neuroendocrine tumors. J Nucl Med. 2011;52:1864\u201370.","journal-title":"J Nucl Med"},{"key":"3395_CR32","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s00259-012-2123-y","volume":"39","author":"L Kabasakal","year":"2012","unstructured":"Kabasakal L, Demirci E, Ocak M, et al. Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET\/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39:1271\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3395_CR33","doi-asserted-by":"crossref","first-page":"364","DOI":"10.2967\/jnumed.112.111724","volume":"54","author":"D Wild","year":"2013","unstructured":"Wild D, Bomanji JB, Benkert P, et al. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET\/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2013;54:364\u201372.","journal-title":"J Nucl Med"},{"key":"3395_CR34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2967\/jnumed.115.166017","volume":"57","author":"E Skoura","year":"2016","unstructured":"Skoura E, Michopoulou S, Mohmaduvesh M, et al. The impact of 68Ga-DOTATAE PET\/CT imaging on management of patients with neuroendocrine tumours: experience from a national referral centre in the United Kingdom. J Nucl Med. 2016;57:34\u201340.","journal-title":"J Nucl Med"},{"key":"3395_CR35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1754-9485.2011.02327.x","volume":"56","author":"MS Hofman","year":"2012","unstructured":"Hofman MS, Kong G, Neels OC, Eu P, Hong E, Hicks RJ. High management impact of Ga-68 DOTATATE (GaTate) PET\/CT for imaging neuroendocrine and other somatostatin expressing tumours. J Med Imaging Radiat Oncol. 2012;56:40\u20137.","journal-title":"J Med Imaging Radiat Oncol"},{"key":"3395_CR36","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1097\/RLU.0b013e31825b2555","volume":"37","author":"J Kunikowska","year":"2012","unstructured":"Kunikowska J, Kr\u00f3licki L, Pawlak D, Zerizer I, Miko\u0142ajczak R. Semiquantitative analysis and characterization of physiological biodistribution of 68Ga-DOTA-TATE PET\/CT. Clin Nucl Med. 2012;37:1052\u20137.","journal-title":"Clin Nucl Med"},{"key":"3395_CR37","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.2967\/jnumed.111.101675","volume":"53","author":"AR Haug","year":"2012","unstructured":"Haug AR, Cindea-Drimus R, Auernhammer CJ, et al. The role of 68Ga-DOTATATE PET\/CT in suspected neuroendocrine tumors. J Nucl Med. 2012;53:1686\u201392.","journal-title":"J Nucl Med"},{"key":"3395_CR38","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1245\/s10434-014-3981-2","volume":"22","author":"H Ilhan","year":"2015","unstructured":"Ilhan H, Fendler WP, Cyran CC, et al. Impact of 68Ga-DOTATATE PET\/CT on the surgical management of primary neuroendocrine tumors of the pancreas or ileum. Ann Surg Oncol. 2015;22:164\u201371.","journal-title":"Ann Surg Oncol"},{"key":"3395_CR39","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00259-013-2371-5","volume":"40","author":"C Schmid-Tannwald","year":"2013","unstructured":"Schmid-Tannwald C, Schmid-Tannwald CM, Morelli JN, et al. Comparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET\/CT in detection of neuroendocrine tumors of the pancreas. Eur J Nucl Med Mol Imaging. 2013;40:897\u2013907.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3395_CR40","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.2967\/jnumed.114.144543","volume":"55","author":"EC Etchebehere","year":"2014","unstructured":"Etchebehere EC, de Oliveira SA, Gumz B, et al. 68Ga-DOTATATE PET\/CT, 99mTc-HYNIC-octreotide SPECT\/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial. J Nucl Med. 2014;55:1598\u2013604.","journal-title":"J Nucl Med"},{"key":"3395_CR41","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00259-012-2286-6","volume":"40","author":"D Putzer","year":"2013","unstructured":"Putzer D, Kroiss A, Waitz D, et al. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0, Tyr3-octreotide versus 68Ga-DOTA0-lanreotide. Eur J Nucl Med Mol Imaging. 2013;40:364\u201372.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3395_CR42","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2967\/jnumed.111.101469","volume":"53","author":"A Pfeifer","year":"2012","unstructured":"Pfeifer A, Knigge U, Mortensen J, et al. Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study. J Nucl Med. 2012;53:1207\u201315.","journal-title":"J Nucl Med"},{"key":"3395_CR43","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/BF00181765","volume":"20","author":"EP Krenning","year":"1993","unstructured":"Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716\u201331.","journal-title":"Eur J Nucl Med"},{"key":"3395_CR44","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s00259-015-3153-z","volume":"42","author":"I Virgolini","year":"2015","unstructured":"Virgolini I, Innsbruck Team. Peptide receptor radionuclide therapy (PRRT): clinical significance of re-treatment? Eur J Nucl Med Mol Imaging. 2015;42:1949\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3395_CR45","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s00259-004-1697-4","volume":"32","author":"D Wild","year":"2005","unstructured":"Wild D, Maecke HR, Waser B, et al. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging. 2005;32:724.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3395_CR46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2337\/diabetes.48.1.77","volume":"48","author":"U Kumar","year":"1999","unstructured":"Kumar U, Sasi R, Suresh S, et al. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes. 1999;48:77\u201385.","journal-title":"Diabetes"},{"key":"3395_CR47","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/00000658-197404000-00005","volume":"179","author":"J Wittingen","year":"1974","unstructured":"Wittingen J, Frey CF. Islet concentration in the head, body, tail and uncinate process of the pancreas. Ann Surg. 1974;179:412\u20134.","journal-title":"Ann Surg"},{"key":"3395_CR48","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s00259-008-0944-5","volume":"36","author":"M Miederer","year":"2009","unstructured":"Miederer M, Seidl S, Buck A, et al. Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET\/CT. Eur J Nucl Med Mol Imaging. 2009;36:48\u201352.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3395_CR49","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2967\/jnumed.113.126177","volume":"55","author":"I Velikyan","year":"2014","unstructured":"Velikyan I, Sundin A, S\u00f6rensen J, et al. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. J Nucl Med. 2014;55:204\u201310.","journal-title":"J Nucl Med"},{"key":"3395_CR50","first-page":"635","volume":"43","author":"L Geworski","year":"2002","unstructured":"Geworski L, Knoop BO, de Wit M, Ivancevi\u0107 V, Bares R, Munz DL. Multicenter comparison of calibration and cross calibration of PET scanners. J Nucl Med. 2002;43:635\u20139.","journal-title":"J Nucl Med"},{"key":"3395_CR51","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2967\/jnumed.108.057455","volume":"50","author":"JS Scheuermann","year":"2009","unstructured":"Scheuermann JS, Saffer JR, Karp JS, Levering AM, Siegel BA. Qualification of PET scanners for use in multicenter cancer clinical trials: the American College of Radiology Imaging Network experience. J Nucl Med. 2009;50:1187\u201393.","journal-title":"J Nucl Med"},{"key":"3395_CR52","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.nucmedbio.2009.11.008","volume":"37","author":"I Velikyan","year":"2010","unstructured":"Velikyan I, Sundin A, Eriksson B, et al. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass. Nucl Med Biol. 2010;37:265\u201375.","journal-title":"Nucl Med Biol"},{"issue":"Suppl 2","key":"3395_CR53","first-page":"487","volume":"36","author":"A Winter","year":"2009","unstructured":"Winter A, Bundschuh RA, Al-Ibraheem A, Buck A, Schwaiger M, Scheidhauer K. Ga-68-DOTATOC PET\/CT - potential pitfalls in the volume of the upper abdomen. Eur J Nucl Med Mol Imaging. 2009;36 Suppl 2:487.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3395_CR54","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12022-014-9317-8","volume":"25","author":"G Kl\u00f6ppel","year":"2014","unstructured":"Kl\u00f6ppel G, Anlauf M, Perren A, Sipos B. Hyperplasia to neoplasia sequence of duodenal and pancreatic neuroendocrine diseases and pseudohyperplasia of the PP-cells in the pancreas. Endocr Pathol. 2014;25:181\u20135.","journal-title":"Endocr Pathol"},{"key":"3395_CR55","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/01.pas.0000194044.01104.25","volume":"30","author":"M Anlauf","year":"2006","unstructured":"Anlauf M, Schlenger R, Perren A, et al. Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol. 2006;30:560\u201374.","journal-title":"Am J Surg Pathol"},{"key":"3395_CR56","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1210\/jc.2006-1944","volume":"92","author":"A Perren","year":"2007","unstructured":"Perren A, Anlauf M, Henopp T, et al. Multiple endocrine neoplasia type 1 (MEN1): loss of one MEN1 allele in tumors and monohormonal endocrine cell clusters but not in islet hyperplasia of the pancreas. J Clin Endocrinol Metab. 2007;92:1118\u201328.","journal-title":"J Clin Endocrinol Metab"},{"key":"3395_CR57","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.2967\/jnumed.115.162719","volume":"56","author":"V Ambrosini","year":"2015","unstructured":"Ambrosini V, Campana D, Polverari G, et al. Prognostic value of 68Ga-DOTANOC PET\/CT SUVmax in patients with neuroendocrine tumors of the pancreas. J Nucl Med. 2015;56:1843\u20138.","journal-title":"J Nucl Med"},{"key":"3395_CR58","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2967\/jnumed.109.068098","volume":"51","author":"C Lois","year":"2010","unstructured":"Lois C, Jakoby BW, Long MJ, et al. An assessment of the impact of incorporating time-of-flight information into clinical PET\/CT imaging. J Nucl Med. 2010;51:237\u201345.","journal-title":"J Nucl Med"},{"key":"3395_CR59","unstructured":"Lum S. Businessman looses lawsuit against cancer centre surgeon. The STRAIT TIMES. Febr 23, 2016, 5:00 AM, SGT. http:\/\/www.straitstimes.com\/singapore\/courts-crime\/businessman-loses-lawsuit-against Accessed 23 Feb 2016."}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-016-3395-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-016-3395-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-016-3395-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T12:26:55Z","timestamp":1567859215000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-016-3395-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,13]]},"references-count":59,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["3395"],"URL":"https:\/\/doi.org\/10.1007\/s00259-016-3395-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,13]]}}}